Sedivention
Key Facts
| Invested since | 2024 |
| Based in | Bavaria |
About the company
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain in obese people, from inside the stomach. The hunger feeling is reduced in a one-off, minimally invasive intervention, similar to a gastroscopy. Our aim is to help obese people lose weight and thus reduce their risk of secondary diseases such as diabetes, hypertension and cancer. And we do this without surgery, without implants, without lifelong medication.
Do you want to
know more about this company?
Sedivention in the news
More startups from Life Sciences
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
To the complete profileof HepaRegeniX
Exit
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
To the complete profileof CARDIOR
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
Exit
Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.
To the complete profileof Sierra Sensors
VACIS is the leading tissue engineering company for body-own blood vessels. The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing …
To the complete profileof Vacis
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
Exit
Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.
To the complete profileof Scopis
Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting …
To the complete profileof Lymphatica
Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …
To the complete profileof cutanos
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, …
To the complete profileof Navan